Q-omics provides the consensus-scored ZMAT1 profile across patient tissues and cancer cell-line models. ZMAT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZMAT1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZMAT1 RNA expression shows 20,556 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where ZMAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMAT1 survival associations across molecular data types. ZMAT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMAT1 RNA expression–survival associations across cancer types. High ZMAT1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, ACC, PAAD and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZMAT1 RNA expression.
This table summarizes ZMAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZMAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMAT1 shows lower tumor expression in BLCA, LUSC, THCA, UCEC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher ZMAT1 RNA expression in tumor versus normal tissue (log2 FC = +0.439, t-test p < 0.001).
This table shows molecular features associated with ZMAT1 in patient tissues and cancer cell lines. In patient samples, ZMAT1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
